Crystal Intelligence and Banxa Announce Strategic Partnership to Enhance Compliance for Embedded Crypto SolutionsSchumer Says Senate Will Vote on Social Security Fairness Act
None
Special Counsel files to drop all federal charges against Trump
The Prime Minister is set to visit British troops serving on Russia’s border as he says Ukraine will require more funding and capability. Sir Keir Starmer was speaking at the Joint Expeditionary Force (JEF) conference in Estonia where he met leaders of other Baltic states. After signing an energy partnership with Norwegian Prime Minister Jonas Gahr Store in Bergen, Sir Keir flew to Estonia where he spoke alongside Mr Store and their Estonian counterpart Kristen Michal. Sir Keir Starmer poses for a group photograph with Baltic leaders (Leon Neal/PA) He added: “A lot of money has been raised, funding has been raised, but more is going to be needed.” The Prime Minister’s also discussed making the economic case at home for continued support for Ukraine. “Now, this is a different world to the world of 10, 20 years ago, to recognise the world that we are living in, there’s a positive case as well to be made. “Defence spending doesn’t sort of sit in a silo over here with no effect on the rest of the economy, no effect on technology. “It has a huge effect on technologies, the cutting edge of technology and change which can then be used in other areas. “It binds countries together. I think all of us have got joint projects on in terms of defence capabilities that bind us together. There’s a huge number of well-paid jobs that are very important to our economy in defence spending as well. “But we have to make that positive case. I don’t personally feel that we can sort of sit back and assume that all of those in our respective countries necessarily accept all of our arguments unless we make them in that positive way, which I do think the argument can and should and must be made. “But the challenge that you put to us is the right challenge, which is it’s very difficult when finances are tight, as they are in all of our countries.” Prime Minister of Estonia Kristen Michal, Norwegian Prime Minister Jonas Gahr Store, and Sir Keir Starmer take part in the JEF Leaders’ Summit in Tallinn, Estonia (Leon Neal/PA) Specialising in the manufacture of the missiles, the rapidly growing company already collaborates closely with the UK defence industry, sourcing a significant portion of its subsystems locally, including from propulsion specialists Roxel in Worcestershire. The Prime Minister will again attend the JEF summit, joining leaders from the Nordics and Baltics to discuss support for Ukraine, the sustained threat posed by Russia and wider European security. He will then visit British forces serving in the region to deter malign Russian threats.Jamie Carragher makes huge Chelsea prediction after 5-1 win over SouthamptonMIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuardTM Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott's contributions and believe he will have an immediate impact.” Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, "The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus.” "I am very excited to join the InspireMD Board at such a transformational time for the company,” added Mr. Ward. "With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal.” Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet ® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com . Forward-looking Statements This press release contains "forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words "intends,” "may,” "will,” "plans,” "expects,” "anticipates,” "projects,” "predicts,” "estimates,” "aims,” "believes,” "hopes,” "potential”, "scheduled” or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's or directors' expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 [email protected] Chuck Padala, Managing Director LifeSci Advisors 646-627-8390 [email protected] [email protected]
Auburn coach Hugh Freeze excited about early signees; players bios includedDeal on Elgin Marbles ‘still some distance’ away, says George Osborne
TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders.
Tel Aviv, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announces transformative initiatives by its wholly owned subsidiary, Fort Products Ltd. (“Fort”), to reshape pest control solutions and online shopping experiences, as previously announced on November 14, 2024 and November 18, 2024. With a creative move, Fort has partnered with leading digital developers to create an AI-based mobile application, offering customers innovative pest control solutions. This platform is designed to identify pests using AI technology to deliver tailored treatment recommendations, providing seamless access to Fort’s top-tier products. The app is expected to launch in the first half of 2025, aiming to enhance Fort’s ecosystem and aiming to position it as a leader in both e-commerce and pest control innovation. In addition, Fort is embracing the future of online payments by integrating cryptocurrency options, including Bitcoin, into its online platform. It is expected that starting in Q1 2025, customers will have the ability to pay with Bitcoin and other major cryptocurrencies to purchase Fort’s pest control solutions on its online platform, reflecting Fort’s commitment to adapting to emerging trends and meeting the preferences of tech-savvy customers globally. AI App Features: Bitcoin Payment Integration Highlights: These developments align with Fort’s vision of blending traditional product excellence with cutting-edge technology, seeking to redefine customer engagement and expand market opportunities globally. About Jeffs’ Brands Ltd Jeffs' Brands aims to transform the world of e-commerce by creating and acquiring products and turning them into market leaders, tapping into vast, unrealized growth potential. Through the Company’s management team’s insight into the FBA Amazon business model, it aims to use both human capability and advanced technology to take products to the next level. For more information on Jeffs’ Brands Ltd visit https://jeffsbrands.com . Forward-Looking Statement Disclaimer This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when discussing successful development of the AI powered mobile app and cryptocurrency payment options, its availability for use by customers, its enhancement of Fort’s product ecosystem, the elevation of Fort’s presence in the pest control sector and in e-commerce, the creation of opportunities for market expansion and customer engagement and the Company’s commitment to adapting to emerging trends. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to adapt to significant future alterations in Amazon’s policies; our ability to sell our existing products and grow our brands and product offerings, including by acquiring new brands; our ability to meet our expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which we operate; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of the conditions in Israel, including the recent attacks by Hamas, Iran, and other terrorist organizations; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (“SEC”), on April 1, 2024 and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact: Michal Efraty Adi and Michal PR- IR Investor Relations, Israel michal@efraty.comTwo charged in connection with Iran drone strike that killed 3 US troops in the Middle Eaststock has seemingly gone straight up since the U.S. election. That more than 80% rise has brought it to new all-time highs. Shares jumped another 6.14% today. And one Wall Street analyst thinks there are good reasons for the recent parabolic move. Wedbush analyst Dan Ives just released a report in which he raised his price target on the stock by $115 per share. His new target is $515, the highest price target for Tesla on Wall Street. Ives sees the recent run in the stock as being logical based on new circumstances brought by the election of Donald Trump. All about self-driving tech Tesla CEO Elon Musk supported Trump monetarily and vociferously before the election. He's now become one of Trump's advisors with a place in the incoming administration. Ives wrote that Musk's new position is a "total game changer for the autonomous and AI [ ] story for Tesla and Musk over the coming years." Many Tesla observers, including Elon Musk, believe that Tesla should be valued more on the potential future income from its self-driving than its existing car sales. Ives believes that a new Trump administration will open the door for that technology to quickly gain traction. Ives doesn't think Tesla stock will stop at $515 per share, either. He believes the self-driving technology -- known as full self-driving, or FSD -- can drive Tesla's valuation to over $2 trillion in the next 12 to 18 months. That would imply a stock price of about $625 per share by the middle of 2026. That's another 35% gain from recent prices. Musk has said that investors shouldn't own Tesla stock if they don't feel it will solve issues associated with autonomous driving. The company has made strides sending out new updates that still require driver supervision. The timing could be right for Tesla's technology to hit the streets with the advanced versions and a friendly administration in the White House. That has investors buying into what Ives published today.
